메뉴 건너뛰기




Volumn 57, Issue 12, 2013, Pages 6110-6121

GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; GRL 04810; GRL 05010; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; FLUORIDE; GRL-04810; GRL-05010; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; OLIGOPEPTIDE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; PYRIDINE DERIVATIVE; SULFONAMIDE;

EID: 84887444174     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01420-13     Document Type: Article
Times cited : (21)

References (55)
  • 1
    • 70350148394 scopus 로고    scopus 로고
    • Understanding hiv-1 latency provides clues for the eradication of long-term reservoirs
    • Coiras M, Lopez-Huertas M, Perez-Olmeda M, Alcami J. 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7:798-812.
    • (2009) Nat. Rev. Microbiol. , vol.7 , pp. 798-812
    • Coiras, M.1    Lopez-Huertas, M.2    Perez-Olmeda, M.3    Alcami, J.4
  • 2
    • 0036846898 scopus 로고    scopus 로고
    • New anti-hiv agents and targets
    • De Clercq. 2002. New anti-HIV agents and targets. Med. Res. Rev. 22: 531-565.
    • (2002) Med. Res. Rev. , vol.22 , pp. 531-565
    • De Clercq1
  • 3
    • 84857690625 scopus 로고    scopus 로고
    • Rodent models for hiv-associated neurocognitive disorders
    • Gorantla S, Poluektova L, Gendelman HE. 2012. Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci. 35:197-208.
    • (2012) Trends Neurosci. , vol.35 , pp. 197-208
    • Gorantla, S.1    Poluektova, L.2    Gendelman, H.E.3
  • 5
    • 3543125970 scopus 로고    scopus 로고
    • A long-term latent reservoir for hiv-1: Discovery and clinical implications
    • Siliciano JD, Siliciano RF. 2004. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54:6-9.
    • (2004) J. Antimicrob. Chemother. , vol.54 , pp. 6-9
    • Siliciano, J.D.1    Siliciano, R.F.2
  • 6
    • 1842613542 scopus 로고    scopus 로고
    • Hiv-1 dynamics in vivo: Implications for therapy
    • Simon V, Ho DD. 2003. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1:181-190.
    • (2003) Nat. Rev. Microbiol. , vol.1 , pp. 181-190
    • Simon, V.1    Ho, D.D.2
  • 7
    • 0043069555 scopus 로고    scopus 로고
    • Toxicity of antiretroviral therapy and implications for drug development
    • Carr. 2003. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2:624-634.
    • (2003) Nat. Rev. Drug Discov. , vol.2 , pp. 624-634
    • Carr1
  • 8
    • 0242539778 scopus 로고    scopus 로고
    • New patterns of hiv-1 resistance during haart
    • Fumero E, Podzamczer D. 2003. New patterns of HIV-1 resistance during HAART. Clin. Microbiol. Infect. 9:1077-1084.
    • (2003) Clin. Microbiol. Infect. , vol.9 , pp. 1077-1084
    • Fumero, E.1    Podzamczer, D.2
  • 9
    • 33746802081 scopus 로고    scopus 로고
    • Differential impact of combination antiretroviral therapy in preventing kaposi's sarcoma with and without visceral involvement
    • Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. 2006. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J. Clin. Oncol. 24:3408-3414.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 3408-3414
    • Grabar, S.1    Abraham, B.2    Mahamat, A.3    Del Giudice, P.4    Rosenthal, E.5    Costagliola, D.6
  • 13
    • 21344455519 scopus 로고    scopus 로고
    • Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus
    • Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. 2005. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 111:194-213.
    • (2005) Virus Res. , vol.111 , pp. 194-213
    • Kramer-Hammerle, S.1    Rothenaigner, I.2    Wolff, H.3    Bell, J.E.4    Brack-Werner, R.5
  • 14
    • 23744505999 scopus 로고    scopus 로고
    • Neurological complications of hiv infection
    • McArthur JC, Brew BJ, Nath A. 2005. Neurological complications of HIV infection. Lancet Neurol. 4:543-555.
    • (2005) Lancet Neurol. , vol.4 , pp. 543-555
    • McArthur, J.C.1    Brew, B.J.2    Nath, A.3
  • 16
    • 33747335917 scopus 로고    scopus 로고
    • Influence of highly active antiretroviral therapy on persistence of hiv in the central nervous system
    • Nath A, Sacktor N. 2006. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 19:358-361.
    • (2006) Curr. Opin. Neurol. , vol.19 , pp. 358-361
    • Nath, A.1    Sacktor, N.2
  • 17
    • 84878784823 scopus 로고    scopus 로고
    • Targeting the glutamatergic system for the treatment of hiv-associated neurocognitive disorders
    • Potter MC, Figuera-Losada M, Rojas C, Slusher BS. 2013. Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J. Neuroimmune Pharmacol. 8:594-607.
    • (2013) J. Neuroimmune Pharmacol. , vol.8 , pp. 594-607
    • Potter, M.C.1    Figuera-Losada, M.2    Rojas, C.3    Slusher, B.S.4
  • 18
    • 0036948147 scopus 로고    scopus 로고
    • The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy
    • Sacktor. 2002. The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 8:115-121.
    • (2002) J. Neurovirol. , vol.8 , pp. 115-121
    • Sacktor1
  • 19
    • 84856452536 scopus 로고    scopus 로고
    • Hiv-associated neurological disorders: A guide to pharmacotherapy
    • Tan IL, McArthur JC. 2012. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 26:123-134.
    • (2012) CNS Drugs , vol.26 , pp. 123-134
    • Tan, I.L.1    McArthur, J.C.2
  • 20
    • 4444235837 scopus 로고    scopus 로고
    • Independent evolution of human immunodeficiency virus (hiv) drug resistance mutations in diverse areas of the brain in hivinfected patients, with and without dementia, on antiretroviral treatment
    • Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIVinfected patients, with and without dementia, on antiretroviral treatment. J. Virol. 78:10133-10148.
    • (2004) J. Virol. , vol.78 , pp. 10133-10148
    • Smit, T.K.1    Brew, B.J.2    Tourtellotte, W.3    Morgello, S.4    Gelman, B.B.5    Saksena, N.K.6
  • 21
    • 0034671498 scopus 로고    scopus 로고
    • Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid hiv rna in hiv-1-infected patients receiving antiretroviral therapy
    • Gisolf EH, Van Praaq R, Jurriaans S, Portegies P, Goudsmit J, Danner SA, Lange JM, Prins JM. 2000. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25:426-433.
    • (2000) J. Acquir. Immune Defic. Syndr. , vol.25 , pp. 426-433
    • Gisolf, E.H.1    Van Praaq, R.2    Jurriaans, S.3    Portegies, P.4    Goudsmit, J.5    Danner, S.A.6    Lange, J.M.7    Prins, J.M.8
  • 24
    • 0032122490 scopus 로고    scopus 로고
    • Cellular and anatomical reservoirs of hiv-1 in patients receiving potent antiretroviral combination therapy
    • Schrager LK, D'Souza MP. 1998. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71.
    • (1998) JAMA , vol.280 , pp. 67-71
    • Schrager, L.K.1    D'Souza, M.P.2
  • 25
    • 0035912198 scopus 로고    scopus 로고
    • Pathways to neuronal injury and apoptosis in hiv-associated dementia
    • Kaul M, Garden G, Lipton SA. 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988-994.
    • (2001) Nature , vol.410 , pp. 988-994
    • Kaul, M.1    Garden, G.2    Lipton, S.A.3
  • 29
    • 0028823560 scopus 로고
    • Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells
    • Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
    • (1995) Antimicrob. Agents Chemother. , vol.39 , pp. 2555-2559
    • Shirasaka, T.1    Chokekijchai, S.2    Yamada, A.3    Gosselin, G.4    Imbach, J.L.5    Mitsuya, H.6
  • 30
    • 8644220502 scopus 로고    scopus 로고
    • Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5h)-furanone: Synthesis of bis-tetrahydrofuranyl ligand for hiv protease inhibitor uic-94017 (tmc-114)
    • Ghosh AK, Leshchenko S, Noetzel M. 2004. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J. Org. Chem. 69:7822-7829.
    • (2004) J. Org. Chem. , vol.69 , pp. 7822-7829
    • Ghosh, A.K.1    Leshchenko, S.2    Noetzel, M.3
  • 31
    • 34250169806 scopus 로고    scopus 로고
    • A novel bis-tetrahydrofuranylurethanecontaining nonpeptidic protease inhibitor (pi), grl-98065, is potent against multiple-pi-resistant human immunodeficiency virus in vitro
    • Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H. 2007. A novel bis-tetrahydrofuranylurethanecontaining nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 51:2143-2155.
    • (2007) Antimicrob. Agents Chemother. , vol.51 , pp. 2143-2155
    • Amano, M.1    Koh, Y.2    Das, D.3    Li, J.4    Leschenko, S.5    Wang, Y.F.6    Boross, P.I.7    Weber, I.T.8    Ghosh, A.K.9    Mitsuya, H.10
  • 32
    • 79953204965 scopus 로고    scopus 로고
    • Novel hiv-1 protease inhibitors (pis) containing a bicyclic p2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-pi-resistant hiv-1 variants
    • Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob. Agents Chemother. 55:1717-1727.
    • (2011) Antimicrob. Agents Chemother. , vol.55 , pp. 1717-1727
    • Ide, K.1    Aoki, M.2    Amano, M.3    Koh, Y.4    Yedidi, R.S.5    Das, D.6    Leschenko, S.7    Chapsal, B.8    Ghosh, A.K.9    Mitsuya, H.10
  • 33
    • 77955348909 scopus 로고    scopus 로고
    • Novel protease inhibitors (pis) containing macrocyclic components and 3(r),3a(s),6a(r)-bis-tetrahydrofuranylurethane that are potent against multi-pi-resistant hiv-1 variants in vitro
    • Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H. 2010. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob. Agents Chemother. 54:3460-3470.
    • (2010) Antimicrob. Agents Chemother. , vol.54 , pp. 3460-3470
    • Tojo, Y.1    Koh, Y.2    Amano, M.3    Aoki, M.4    Das, D.5    Kulkarni, S.6    Anderson, D.D.7    Ghosh, A.K.8    Mitsuya, H.9
  • 36
    • 78049524808 scopus 로고    scopus 로고
    • In vitro selection of highly darunavir-resistant and replication- competent hiv-1 variants by using a mixture of clinical hiv-1 isolates resistant to multiple conventional protease inhibitors
    • Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J. Virol. 84:11961-11969.
    • (2010) J. Virol. , vol.84 , pp. 11961-11969
    • Koh, Y.1    Amano, M.2    Towata, T.3    Danish, M.4    Leshchenko-Yashchuk, S.5    Das, D.6    Nakayama, M.7    Tojo, Y.8    Ghosh, A.K.9    Mitsuya, H.10
  • 38
    • 34248664984 scopus 로고    scopus 로고
    • Adsorption of drugs onto aph responsive poly(n,n dimethyl aminoethyl methacrylate) grafted anion-exchange membrane in vitro
    • Karppi J, Akerman S, Akerman K, Sundell A, Nyyssonen K, Penttila I. 2007. Adsorption of drugs onto apH responsive poly(N,N dimethyl aminoethyl methacrylate) grafted anion-exchange membrane in vitro. Int. J. Pharm. 338:7-14.
    • (2007) Int. J. Pharm. , vol.338 , pp. 7-14
    • Karppi, J.1    Akerman, S.2    Akerman, K.3    Sundell, A.4    Nyyssonen, K.5    Penttila, I.6
  • 39
    • 50549096031 scopus 로고    scopus 로고
    • Fluorinated nucleosides: Synthesis and biological implication
    • Liu P, Sharon A, Chu CK. 2008. Fluorinated nucleosides: synthesis and biological implication. J. Fluor. Chem. 129:743-766.
    • (2008) J. Fluor. Chem. , vol.129 , pp. 743-766
    • Liu, P.1    Sharon, A.2    Chu, C.K.3
  • 41
    • 34748815589 scopus 로고    scopus 로고
    • Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells
    • Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, Nakaoke R, Kataoka Y, Niwa M. 2007. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 27:687-694.
    • (2007) Cell. Mol. Neurobiol. , vol.27 , pp. 687-694
    • Nakagawa, S.1    Deli, M.A.2    Nakao, S.3    Honda, M.4    Hayashi, K.5    Nakaoke, R.6    Kataoka, Y.7    Niwa, M.8
  • 43
    • 33845968810 scopus 로고    scopus 로고
    • Screening and selecting for optimized antiretroviral drugs: Rising to the challenge of drug resistance
    • de Bethune MP, Hertogs K. 2006. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr. Med. Res. Opin. 22:2603-2612.
    • (2006) Curr. Med. Res. Opin. , vol.22 , pp. 2603-2612
    • De Bethune, M.P.1    Hertogs, K.2
  • 45
    • 84870533547 scopus 로고    scopus 로고
    • Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared to lopinavir/ritonavir in hiv-1-infected treatment-naive patients in the artemis trial
    • Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared to lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 14:49-59.
    • (2013) HIV Med. , vol.14 , pp. 49-59
    • Orkin, C.1    DeJesus, E.2    Khanlou, H.3    Stoehr, A.4    Supparatpinyo, K.5    Lathouwers, E.6    Lefebvre, E.7    Opsomer, M.8    Van De Casteele, T.9    Tomaka, F.10
  • 50
    • 84876207904 scopus 로고    scopus 로고
    • Grl-0519, a novel oxatricyclic ligand-containing nonpeptidic hiv-1 protease inhibitor (pi), potently suppresses replication of a wide spectrum of multi-pi-resistant variants in vitro
    • Amano M, Tojo Y, Salcedo-Gomez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H. 2013. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant variants in vitro. Antimicrob. Agents Chemother. 57:2036-2046.
    • (2013) Antimicrob. Agents Chemother. , vol.57 , pp. 2036-2046
    • Amano, M.1    Tojo, Y.2    Salcedo-Gomez, P.M.3    Campbell, J.R.4    Das, D.5    Aoki, M.6    Xu, C.X.7    Rao, K.V.8    Ghosh, A.K.9    Mitsuya, H.10
  • 54
    • 65449179589 scopus 로고    scopus 로고
    • Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log d limits based on permeability
    • Waring MJ. 2009. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability. Bioorg. Med. Chem. Lett. 19:2844-2851.
    • (2009) Bioorg. Med. Chem. Lett. , vol.19 , pp. 2844-2851
    • Waring, M.J.1
  • 55
    • 19444368758 scopus 로고
    • Organisation for Economic Cooperation and Development. Test no. 107. Organisation for Economic Cooperation and Development, Paris, France. doi:10.1787/20745753
    • Organisation for Economic Cooperation and Development. 1995. OECD guidelines for the testing of chemicals, section 1: physical-chemical properties. Test no. 107. Organisation for Economic Cooperation and Development, Paris, France. doi:10.1787/20745753.
    • (1995) OECD Guidelines for the Testing of Chemicals, Section 1: Physical-Chemical Properties


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.